Amneal Pharmaceuticals has announced its acquisition of Kashiv BioSciences to strengthen its global biosimilars platform, combining R&D, manufacturing, and commercial capabilities.
Glimpse:
Amneal Pharmaceuticals is acquiring Kashiv BioSciences in a deal valued at up to $1.1 billion, aiming to build a fully integrated biosimilars platform. The move will enhance its pipeline, manufacturing strength, and global reach in the rapidly growing biosimilars market.
Amneal Pharmaceuticals has entered into a definitive agreement to acquire Kashiv BioSciences, marking a major strategic move to expand its capabilities in the biosimilars segment. The deal, valued at up to $1.1 billion, includes a mix of cash, equity, and milestone based payments, reflecting the scale and ambition of the transaction.
The acquisition combines Kashiv’s strong expertise in biosimilar development and manufacturing with Amneal’s established commercial and distribution capabilities. Together, the companies aim to create a fully integrated, end to end biosimilars platform capable of accelerating product development and global market access.
This move comes at a pivotal time for the pharmaceutical industry, as biologic drugs worth over $300 billion are expected to lose patent protection over the next decade. This creates a massive opportunity for biosimilars lower cost alternatives that improve access to life saving biologic therapies.
By leveraging Kashiv’s R&D and manufacturing strengths alongside Amneal’s commercial scale, the combined entity aims to accelerate its biosimilars pipeline, enabling multiple product launches annually and strengthening its position in the U.S. and global markets.
The transaction is subject to shareholder and regulatory approvals and is expected to close in the second half of 2026. Once completed, it is expected to significantly enhance Amneal’s long term growth profile and position it as a key player in the next wave of affordable biologic medicines.
“This acquisition positions us to lead the next wave of affordable biologic medicines worldwide.”
By
HB Team
Related News
